Amgen announced plans to invest over $600 million into a state-of-the-art Center for Science and Innovation at its Thousand Oaks, California headquarters. Designed to integrate multidisciplinary teams and embrace advanced automation and digital capabilities, the center aims to accelerate discovery of next-generation therapeutics across serious diseases. Construction commencement is slated for Q3 2025, with anticipated creation of hundreds of U.S.-based jobs. This substantial building project complements Amgen’s broader $32 billion U.S. manufacturing commitment, underscoring the company’s long-term domestic investment strategy in R&D and biomanufacturing excellence.